Division of Biomedical Sciences, School of Medicine, University of California Riverside, Riverside, CA 92521.
Department of Biochemistry, College of Natural and Agricultural Sciences, University of California Riverside, Riverside, CA 92521.
Proc Natl Acad Sci U S A. 2024 Nov 19;121(47):e2403330121. doi: 10.1073/pnas.2403330121. Epub 2024 Nov 12.
The concept of targeted protein degradation is at the forefront of modern drug discovery, which aims to eliminate disease-causing proteins using specific molecules. In this paper, we explored the idea to design protein degraders based on the section of ligands that cause protein destabilization, hence that facilitate the cellular breakdown of the target. Our studies present covalent agents targeting Pin1, a cis-trans prolyl isomerase that plays a crucial role in tumorigenesis. Our design strategy entailed iterative optimizations of agents for potency and Pin1 destabilization in vitro. Biophysical and cellular studies suggest that the agents may act like , displacing protein-stabilizing interactions that open the structure for recognition by the proteasome degradation machinery. This approach resulted in a series of potent and effective Pin1 degraders with potential applications in target validation and in therapeutic development. We propose that our design strategy can identify molecular degraders without engineering bifunctional agents that artificially create interactions between a disease-causing protein and a ubiquitin ligase.
靶向蛋白降解的概念是现代药物发现的前沿领域,其目的是使用特定的分子来消除致病蛋白。在本文中,我们探讨了基于导致蛋白质不稳定的配体部分设计蛋白质降解剂的想法,从而促进靶标的细胞分解。我们的研究提出了针对 Pin1 的共价试剂,Pin1 是一种顺反式脯氨酰异构酶,在肿瘤发生中起着关键作用。我们的设计策略包括对体外效力和 Pin1 不稳定的试剂进行迭代优化。生物物理和细胞研究表明,这些试剂可能像分子胶一样,置换蛋白质稳定相互作用,从而为蛋白酶体降解机制的识别打开结构。这种方法产生了一系列有效的 Pin1 降解剂,具有在靶标验证和治疗开发方面的潜在应用。我们提出,我们的设计策略可以识别分子降解剂,而无需设计人工在致病蛋白和泛素连接酶之间创建相互作用的双功能试剂。